The FDA first approved Stivarga in September 2012 to treat colorectal cancer patients who don’t respond to initial treatments. Now, the drug can also be used as a second-line treatment for hepatocellular carcinoma, the most common type of liver cancer.
Stivarga’s expanded approval marks the first new treatment for liver cancer in nearly a decade, according to the FDA.
More articles on supply chain:
Corporate Whistleblower Center encourages pharma employees to report unsanitary drug plant conditions
7 must-reads for supply chain leaders this week
Dem. Senators pen letter to Dr. Scott Gottlieb on FDA hiring freeze
